Loading
Nanoparticles / Papillomavirus Infections / Disease Models, Animal · Journal article
Human Vaccines & Immunotherapeutics · June 16, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical murine study reports that HPV16 E7 mRNA/LNP vaccine achieved tumor regression, undetectable HPV16 E6/E7 DNA, and durable immune memory in both therapeutic (initiated 3 days post-implantation) and preventive (pre-implantation) settings using low tumor burden (5,000–10,000 TC-1 cells). E7 vaccination outperformed E6 across regimens. No human efficacy, clinical comparators, or long-term safety data are provided.
Preclinical murine tumor model study with preventive and therapeutic arms. Female mice (strain not specified) implanted with HPV16-positive TC-1 tumor cells at low inoculum (5,000–10,000 cells) to model early-intervention HPV disease. Intervention: HPV16 E7 mRNA/LNP vaccine, administered intramuscularly at 1 µg (low-dose, single), 10 µg (single therapeutic dose), or 10 µg + 5 µg (two-dose therapeutic regimen), or two 5 µg doses (preventive regimen). Compared with: HPV16 E6 mRNA/LNP vaccine; E7 versus E6 compared within study; NSS (normal saline solution) control mentioned in graphical abstract. Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
E7 mRNA/LNP induced stronger antigen-specific T cell responses than E6 at 1 µg intramuscular dose Therapeutic E7 vaccination (10 µg single or 10 µg + 5 µg two-dose) elicited robust T cell responses, significant tumor regression, and undetectable HPV16 E6/E7 DNA Preventive E7 vaccination (two 5 µg doses) prevented tumor establishment following TC-1 cell inoculation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding supports further development of HPV16 E7 mRNA/LNP as a therapeutic vaccine candidate for HPV-associated disease, particularly in early-stage disease with low tumor burden. Clinical trials are needed to establish human efficacy, safety, and optimal dosing.
Preclinical murine tumor model study demonstrating HPV16 E7 mRNA/LNP vaccine efficacy in early-intervention setting, with no human data or comparator arm against standard therapy.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding supports further development of HPV16 E7 mRNA/LNP as a therapeutic vaccine candidate for HPV-associated disease, particularly in early-stage disease with low tumor burden. Clinical trials are needed to establish human efficacy, safety, and optimal dosing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Persistent infection with high-risk human papillomavirus (HPV) drives the development of cervical and other anogenital cancers, with limited therapeutic options for early-stage disease and precancerous lesions. There is a critical unmet need for effective therapeutic vaccines capable of inducing durable immune responses to eliminate early tumor cells and prevent disease progression. In this study, we developed lipid nanoparticle (LNP)-formulated mRNA vaccines encoding HPV16 E6 and E7 oncoproteins and evaluated their efficacy in a murine model using a low tumor inoculum (5,000-10,000 TC-1 cells) to represent a low tumor burden, early-intervention setting. E7 mRNA/LNP induced stronger antigen-specific T cell responses than E6 when administered intramuscularly at a low dose (1 µg). In therapeutic settings, initiated 3 d after tumor implantation, either as a single 10 µg dose or a two-dose regimen (10 µg followed by 5 µg, 6 d apart), E7 vaccination elicited robust T cell responses, significant tumor regression, and undetectable HPV16 E6/E7 DNA, outperforming E6 across regimens. In the preventive setting, administration of two 5 µg doses of HPV16 E7 prevented tumor establishment following TC-1 cell inoculation. Importantly, E7 vaccination induced durable immune memory, as demonstrated by sustained tumor protection and undetectable HPV E6/E7 DNA upon rechallenge at 5 months. These findings highlight the potential of HPV16 E7 mRNA/LNP as a therapeutic vaccine targeting low tumor burden HPV-associated disease and support further clinical development. A multivalent mRNA vaccine targeting multiple high-risk HPV genotypes is currently under development.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.